LSTA Earnings

LSTA reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 0.00 against an estimate of 90.00K, resulting in a 0% surprise. The EPS was -0.49, surpassing the expected -0.54 by 9.26% . The stock experienced a -12.34% price change on the earnings day and a -8.09% change over the next five days, reflecting market reactions to the results.

Following LSTA's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -12.34% on the day of the release. Over the subsequent five days, it saw a -8.09% change. Historically, LSTA's stock price tends to shift by an average of +1.60% in the 10 days leading up to earnings and -0.57% in the 10 days following, providing insight into potential market.

For , analysts estimate LSTA’s annual revenue to reach undefined, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between LSTA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, LSTA's stock price typically moves by +1.60% in the 10 days before its earnings and -0.57% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.00 and revenue of undefined.

The earnings call summary presents a mixed outlook. The financial performance shows a decrease in expenses and net losses, which is positive. However, the Q&A reveals uncertainties, particularly regarding the timing of trial data and funding for the ASCEND Phase III trial. The market has not reacted positively to clinical data, and management's responses were sometimes vague. The strategic plan highlights promising collaborations and trials, but the lack of immediate catalysts and macroeconomic challenges temper the sentiment. Overall, the sentiment is neutral, reflecting a balance of positive financial health and uncertainties in execution.